TY - JOUR
T1 - The role of mobile health technologies in allergy care
T2 - An EAACI position paper
AU - Matricardi, Paolo Maria
AU - Dramburg, Stephanie
AU - Alvarez-Perea, Alberto
AU - Antolín-Amérigo, Darío
AU - Apfelbacher, Christian
AU - Atanaskovic-Markovic, Marina
AU - Berger, Uwe
AU - Blaiss, Michael S.
AU - Blank, Simon
AU - Boni, Elisa
AU - Bonini, Matteo
AU - Bousquet, Jean
AU - Brockow, Knut
AU - Buters, Jeroen
AU - Cardona, Victoria
AU - Caubet, Jean Christoph
AU - Cavkaytar, Özlem
AU - Elliott, Tania
AU - Esteban-Gorgojo, Ignacio
AU - Fonseca, Joao A.
AU - Gardner, James
AU - Gevaert, Philippe
AU - Ghiordanescu, Ileana
AU - Hellings, Peter
AU - Hoffmann-Sommergruber, Karin
AU - Fusun Kalpaklioglu, A.
AU - Marmouz, Farid
AU - Meijide Calderón, Ángela
AU - Mösges, Ralph
AU - Nakonechna, Alla
AU - Ollert, Markus
AU - Oteros, José
AU - Pajno, Giovanni
AU - Panaitescu, Catalina
AU - Perez-Formigo, Daniel
AU - Pfaar, Oliver
AU - Pitsios, Constantinos
AU - Rudenko, Michael
AU - Ryan, Dermot
AU - Sánchez-García, Silvia
AU - Shih, Jennifer
AU - Tripodi, Salvatore
AU - Van der Poel, Lauri Ann
AU - van Os-Medendorp, Harmieke
AU - Varricchi, Gilda
AU - Wittmann, Jörn
AU - Worm, Margitta
AU - Agache, Ioana
N1 - Funding Information:
Dr. Matricardi reports personal fees from TPS, outside the submitted work; Dr. Blank reports non‐financial support from ALK‐Abelló, grants, personal fees and non‐financial support from Bencard Allergie GmbH, personal fees from Teomed AG , grants and personal fees from Thermo Fisher Scientific, grants from Allergy Therapeutics, outside the submitted work. Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work; Dr. Fonseca reports personal fees from AstraZeneca, GSK, Novartis, Teva, grants from Novartis, Mundipharma, outside the submitted work; and I'm a partner at MEDIDA, Lda, a small company developing mHealth technologies. Dr. Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, personal fees from Allergopharma, personal fees from Stallergenes, outside the submitted work; Dr. Hoffmann Sommergruber reports grants from Austrian Science Funds, outside the submitted work; .Dr. Mösges reports personal fees from ALK, grants from ASIT biotech, personal fees from allergopharma, personal fees from Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non‐financial support from Lofarma, non‐financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, personal fees from Hexal, personal fees from Servier, personal fees from Klosterfrau, non financial support from Atmos, personal fees from Bayer, non‐financial support from Bionorica, personal fees from FAES, personal fees from GSK, personal fees from MSD, personal fees from Johnson&Johnson, personal fees from Meda, personal fees and non‐financial support from Novartis, non‐financial support from Otonomy, personal fees from Stada, personal fees from UCB, non‐financial support from Ferrero, grants from BitopAG, grants from Hulka, personal fees from Nuvo, grants from Ursapharm, personal fees from Menarini, personal fees from Mundipharma, personal fees from Pohl‐Boskamp, outside the submitted work; .Dr. Pfaar reports grants and personal fees from ALK‐Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Nuvo, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from MEDA Pharma/MYLAN, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor Biotechnologies, grants from Glaxo Smith Kline, personal fees from Astellas Pharma Global, outside the submitted work; .Dr. Tripodi declares to be a cofounder of TPS Productions srl who developed the app Allergymonitor. Dr. van Os‐Medendorp reports non financial support from EAACI, during the conduct of the study; grants from Vrienden UMC Utrecht, outside the submitted work; .Dr. Van der Poel reports to be a shareholder with a honorary clinical advisory role at foormaetro. She declares not having received any financial compensation for this work to date. Dr. Shih reports other from Takeda, other from Teva, other from Astrazenaca, outside the submitted work. The rest of the Authors declare that they have no relevant conflict of interest.
Publisher Copyright:
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health-related services, data and information flow, patient self-management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the “Be He@lthy, Be Mobile” WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the “General Data Protection Regulation” and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician- to patient-centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed.
AB - Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health-related services, data and information flow, patient self-management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the “Be He@lthy, Be Mobile” WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the “General Data Protection Regulation” and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician- to patient-centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed.
KW - EAACI
KW - allergy
KW - digital health
KW - mobile health technology
KW - position paper
UR - http://www.scopus.com/inward/record.url?scp=85079563718&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/31230373
U2 - 10.1111/all.13953
DO - 10.1111/all.13953
M3 - Article
C2 - 31230373
AN - SCOPUS:85079563718
SN - 0105-4538
VL - 75
SP - 259
EP - 272
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 2
ER -